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Background: The prevalence of undiagnosed diabetes mellitus (DM) in Greenland has been reported very high
with only 30% of cases diagnosed. In 2010, glycosylated hemoglobin (A1C) was introduced as a diagnostic tool in
Greenland. However, the current use of A1c is unknown as well as the current prevalence of diagnosed DM.
The aim of this study was firstly to estimate the use of A1C as diagnostic tool within the first 27 months after
introducing the method and secondly to estimate the age and gender specific prevalence of diagnosed DM in
Greenland in 2012.
Methods: This study was perfomed as a cross-sectional register study using data from electronic medical records
(EMR). To analyse the use of A1C as diagnostic tool:
A sample amongst all Greenlanders at or above age 35 old was used to determine the number of individuals
screened with A1C within a 27 month period, excluding those already known to have DM.
To estimate the prevalence of diagnosted DM: Patients with DM were identified electronically using a statistic
module run on data in the EMR. Age and gender specific prevalence was estimated using the Greenlandic
population as of 1 January 2012 as the background population.
Results: The test sample resulted in a study group of 1008 individuals from which 2.3% (23) were excluded
because they were already known to have DM. Among the remaining 985, 13.6% were tested with A1C at least
once during the 27 months of observation. DM was diagnosed in 7.5% (10) of the tested persons and in 1.0% of
the whole group.
Regarding prevalence, a total of 920 patients with diagnosed DM were identified. The total prevalence among
adults aged 20–79 years old was 2.20% (95% CI: 2.05-2.34) with no significant difference between genders.
Conclusion: Testing for DM using A1C as diagnostic tool is used in Greenland. The prevalence of diagnosed DM in
Greenland remains low although increasing. Undiagnosed DM may still be an important issue in Greenland.
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Greenland has undergone a rapid transition during the
last half century from a traditional Inuit society domi-
nated by small communities, villages and settlements to
a modern society [1]. Within a few decades (1950s to
1970s), Greenland was transformed from a traditional
hunting society to a modern society where most people* Correspondence: milp@peqqik.gl
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distribution, and reproduction in any mediumnow rely on wage earning [1]. These profound social and
cultural change have been followed by a health transition
with an increasing prevalence of lifestyle related diseases
like overweight, obesity, diabetes and ischemic heart
diseases [2-7] similar to what has occured among Inuit
in Alaska and Canada [8-10].
Thus, diabetes mellitus (DM) used to be very rare (less
than 1% of the population) in Greenland [11]. However,
epidemiological studies have indicated a high prevalence
of diabetes at around ten percent among adult
Greenlanders based on oral glucose tolerance tests [6]Med Central Ltd. This is an open access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ulations in Canada and Alaska [12-15]. However, seventy
to eighty percent of cases were undiagnosed indicating
low diagnostic activity [6,16].
In 2008, a national diabetes program was implemented
in the primary health care system in Greenland aiming
to improve the diabetes care including diagnostic activity
and screening for diabetic complications. Along with
increasing quality of care, the prevalence of diagnosed
type 2 diabetes mellitus (T2DM) rose by 19% within two
years from 1.97% to 2.3% among adult Greenlanders at
or above 40 years old [17]. However, the prevalence of
diagnosed T2DM was still much lower than reported in
the surveys of the population [6,16].
In order to optimize the diagnostic procedure of diabetes
and to make case finding more feasible in Greenland, the
diagnostic strategy was changed by the first of June 2010.
From that date glycosylated hemoglobin (A1C) was intro-
duced as a screening tool [18,19] in Greenland conse-
quently replacing the former use of fasting whole blood
glucose testing [20]. Neither the diagnostic activity nor the
prevalence of diagnosed diabetes mellitus has been evalu-
ated after the introduction of A1C as a diagnostic tool.
The aim of this study was first to describe within the
first twenty-seven months after introducing A1C as a
diagnostic strategy the diagnostic activity with A1C as a
screening tool and second, to estimate the age and gen-
der specific prevalence of diagnosed diabetes mellitus in
Greenland in 2012.
Materials and methods
The study was designed as two cross-sectional observa-
tional register studies of the Greenlandic population. Ob-
servational data were collected retrospectively through the
Electronic Medical Record (EMR) implemented through-
out the whole Greenlandic primary health care system in
the autumn of 2007.
Setting
Greenland is the largest island in the world covering an
area of over 2 million km2 [21]. The country is sparsely
populated with approximately 56,000 inhabitants living1008 persons above 35 years old living 
in Greenland
(564 males, 444 females)
(Mean age 52 (11) years old)
23 persons with diagnosed diabetes 
before June 2010
(10 males, 13 females)
985 without diabetes
(554 males, 431 females)
(Mean age 52 (11) years old)   
Figure 1 Flow chart showing the persons in the study sample 1.along the coast in 18 towns and around 60 minor settle-
ments. Furthermore, the country is divided into 4 govern-
mental regions and 5 health regions [22]. Approximately
90% of the population is of Greenlandic origin (native
Inuit); the last 10% are immigrants (mostly Danes) [21].
Primary health care is free to all inhabitants and pro-
vided locally in primary health care clinics. Since 2008
all patients diagnosed with diabetes mellitus have been
coded with “D” in the EMR.
Measurements of A1C were performed at The Central
Laboratory at Queen Ingrid Hospital in Nuuk, using
Architecht® 8000T (Abbott Laboratories) based on an
enzymatic technique. The Central Laboratory is a mem-
ber of the Danish quality control system for laboratories,
DEKS. In addition some of the analyses of A1C have
been performed locally using DCA vantage® (Siemens
Healthcare Diagnostics) based on an immunological tech-
nique. Results of the tests were recorded in the electronic
lab card for Greenland (BBC) and/or directly in the lab
card in the EMR. A confirmed value of A1C at or above
48 mmol/mol (6.5%) is used as diagnostic for diabetes
mellitus in Greenland as recommended by the American
Diabetes Association [18].
Study populations and analysis
Use of A1C as diagnostic tool – study sample 1
The first study population was defined as anyone affili-
ated with a primary health clinic in Greenland, who was
born on the 1st of any month of the year before first of
January 1978. Thus only adults at or above 35 years old
where included.The cut-off age was chosen because most
cases of undiagnosed diabetes in Greenland occur among
adults [6,16]. We registered their age and gender. Individ-
uals who were diagnosed with diabetes (coded with “D”)
in their medical record before 1st of June 2010 were
excluded from the study group. Among the remaining
study sample we registered the number of persons
screened with A1C and the number of persons who were
actually diagnosed with diabetes during the 27 months
period. The proportion of persons without diagnosed
diabetes that was screened with A1C within the study
period was used to describe the diagnostic activity.23 (100 %) had a HbA1c test performed 
(Mean age  64 (12) years old)
(Mean AC1 7.4 (1.9) %)
134 (13.6%) had a HbA1c test 
performed 
(Mean age 54 (11) years old)
(Mean AC1 5.3(0.6) %)
10 (7.5 %) were diagnosed with 
diabetes
(5 males, 5 females)
(Mean age 55 (8) years old)
(Mean AC1 7.5 (1.5) %)
Table 1 Age and gender specific prevalence of diabetes
mellitus in Greenland
Age (years) Male Female P
Prevalence % Prevalence %
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The second study population was identified as all pa-
tients coded with “D” in the EMR using an electronically
search module (data extraction September 2012). The
age and gender specific prevalence was calculated using
the Greenlandic population as of 1 January 2012 as the
background population [21]. The prevalence of diag-
nosed diabetes mellitus among adults at or above 20
years old was estimated in the present study (2012)—as
well as for 2008 and 2010 studies—based on data pub-
lished in 2011 [17].
Statistics
Crude prevalence was reported for age and gender spe-
cific groups using 95% confidence intervals. Chi-square
tests were used to compare frequencies between two
groups, and chi-square tests for trends were used to
examine prevalence rates with increasing age and over
time. P-value at 0.05 was used as level of significance.
The ethics committee for medical research in Greenland
has approved the study with reference number 2013-5.
Results
Use of A1C as diagstic tool – study sample
A total of 1008 individuals born before the first of Janu-
ary 1978 on the first day of a month, living in Greenland
as of September 2012 were identified (see Figure 1). Of
those, 2.3% (23) were diagnosed with diabetes mellitus
before the study period (before the first of June 2010).
Among the remaining 985 individuals, 13.6% (134) were
tested for diabetes mellitus utilizing measurement(s) of
A1C at least once during the 27 months of observation.
Diabetes mellitus was diagnosed in 7.5% (10) of the
tested persons and in 1.0% of the whole group (985).
Prevalence of diagnosed diabetes mellitus –study sample 2
A total of 920 patients with diagnosed diabetes mellitus
were identified. The age and gender specific prevalences
of diabetes mellitus are illustrated in Table 1 and Figure 2.
The total prevalence among adults aged 20–79 years old
was 2.20% (95% CI: 2.05-2.34) with no significant differ-
ence between the genders (p=0.945). The prevalence in-
creased with age for both males (p<0.001) and females
(p<0.001). The prevalence among patients at or above 20
years old documented in this study is illustrated in Table 2
together with prevalence calculated from earlier published
data [17]. The prevalence of diagnosed diabetes mellitus is
still increasing in Greenland (p<0.001).
Discussion
The principal finding in this study was that 13.6% of
adults at or above 35 years have been tested for diabetes
using A1C as the diagnostic tool, indicating that A1c is
used as a diagstic tool in Greenland in this age group.Approximately, 7.5% of the tested persons were diag-
nosed with diabetes mellitus indicating that undiagnosed
diabetes mellitus is still an issue and active case-finding
searches relevant. Furthermore, the prevalence of diag-
nosed diabetes mellitus in Greenland documented in this
study is the highest reported so far indicating increasing
prevalence.
Strength and weakness
The major strength in this study was that the whole
population of Greenland was included. All A1C test re-




















Figure 2 Age and gender specific prevalence of diabetes mellitus in Greenland 2012.
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study. The actual number of patients tested for diabetes
in the study period may therefore be underestimated.
Furthermore, the increasing prevalence of diagnosed dia-
betes observed in the study period reflects the whole
diagnostic activity in Greenland and not only the A1C
diagnostic activity. Use of whole blood capillary testing
may also have contributed to the diagnostic process be-
cause new guidelines can not be implemented immedi-
ately nationally.
Another limitation in this study is the unknown diag-
nostic activity of diabetes mellitus before introducing the
A1C. Thus, the results mainly describe baseline diagnos-
tic activity in Greenland after implementation of the
new diagnostic criteria.
A possibly weakness in this study concerns the estima-
tion of the prevalence of diagnosed diabetes mellitus.
Only patients that were actually coded with ”D” in the
electronic medical record were included in the study.
This may lead to an underestimation of the true preva-
lence of diagnosed diabetes mellitus. However, patients
without a ”D” code who receive prescriptions electronic-
ally for glucose lowering drugs, have their medical record
reviewed annually, a process intended to identify patients
with diabetes yet no “D” code. Thus the underestimation
is not likely to be of any significant magnitude.
Use of A1C as diagstic tool
The use of A1C as diagnostic toolwithin the first 27
month after introducing the new strategy underlines the
feasibility in a Greenlandic context of using this method.Table 2 Prevalence of diagnosed diabetes mellitus among ad
Year 2008*




*[19] **Ninety percent of the population included in 2008.A1C testing can be performed in contrast to fasting
whole blood glucose tests or oral glucose tolerance tests
without the delay of waiting on fasting individuals. On
the other hand it is obvious that the diagnoses using
A1C criteria are not exactly the same as those diagnosed
on plasma glucose [19,23-25]. Also, ethnical differences
have been suggested as proving problematic when using
HbA1c diagnosis. Thus, in most cases a lower number
of patients are diagnosed using A1C criteria than when
using oral glucose tolerance tests. This discrepancy has
also been demonstrated among Greenlanders where the
prevalence of diabetes based on oral glucose tolerance
test resulted in 7.0% compared to 3.9% using the A1C
criteria [24]. Similary, the prevalence of diabetes based
on oral glucose tolerance compared to A1C criteria was
higher in United Kingdom (3.7% versus 1.0%), Australia
(4.0% versus 0.7%) and Kenya (3.4% versus 1.4%) while
the opposite was the case in Denmark (4.2% versus
6.7%) and India (10.2 5 versus 12.9%) [24].
However, the obvious convenience of A1C might in-
crease the number of patients tested and diagnosed with
diabetes tested [23]. Furthermore, it seems evident that
the most severe cases and consequently those that might
benefit most from treatment are those that are diag-
nosed using A1C [26-29]. Using A1C as a diagnostic tool
instead of the former use of whole blood capillary glucose
(and not plasma glucose as recommended internationally)
brings the diagnostic procedure in accordance with the
most recent international guidelines [18].
Finally, in a sparsely populated country like Greenland
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diagnostic setup for an upcoming disease like diabetes.
Prevalence of diagnosed diabetes mellitus
Increasing prevalence of diabetes is seen all over the
world. In accordance with that we have found an in-
creasing prevalence in this study compared to previous
studies [17].
The increase has been documented withih the last five
years and is most likely due to increased diagnostic ac-
tivity. Improved treatment and increased survival among
patients with diabetes along with an actual increase in
the prevalence can also contribute to an increasing over-
all prevalence.
However, in a global perspective the prevalence of di-
agnosed diabetes remains quite low [30]. Undiagnosed
patients still seem to be quite common. Perhaps there-
fore the 7.5% of individuals tested for DM were actually
diagnosed with DM, which could indicate that the over-
all percentage of undiagnosed patients with DM was
around 7.5% - around the double of the prevalence of di-
agnosed DM However, most likely, the individuals tested
with A1C are not a random sample of the population
and rather represent individuals with increased risk of
diabetes, making the percentage of undiagnosed cases
among the total population less than 7.5%.
Conclusion
In conclusion, testing for DM using A1C as diagnostic
tool is used in Greenland. The prevalence of diagnosed
DM in Greenland although increasing remains low in a
global perspective. Undiagnosed DM may still be an im-
portant issue in Greenland.
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